TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2182604

Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-interferon
Number of subjects: 0
Study: 375722

Group type: EXPERIMENTAL
Intervention: Treatment for mild hypertension
Number of subjects: 22700
Study: 30758261

Group type: EXPERIMENTAL
Intervention: Mediterranean diet for 4 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Western diet for 4 days
Number of subjects: 11
Study: 30058184

Group type: EXPERIMENTAL
Intervention: Outpatient multidisciplinary therapy (36 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study: 27292817

Group type: EXPERIMENTAL
Intervention: levomilnacipran ER
Number of subjects: 2598
Study: 24703170

Group type: EXPERIMENTAL
Intervention: Adjunctive medroxyprogesterone acetate (MPA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 51

Group type: COMPARATOR
Intervention: Adjunctive tamoxifen
Number of subjects: 51
Study: 22018458

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 20
Study: 20401702

Group type: EXPERIMENTAL
Intervention: Exclusive breast feeding (Group 1, n=26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fortified breast feeding (Group 2, n=26)
Number of subjects: 52
Study: 18076273

Group type: COMPARATOR
Intervention: Multiple Sets (MS; n = 18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single Set (SS; n = 14)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (C; n = 8)
Number of subjects: 40
Study: 16150765

Group type: EXPERIMENTAL
Intervention: Social behaviour and network therapy
Number of subjects: 742

Group type: COMPARATOR
Intervention: Motivational enhancement therapy
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 742
Study: 12582946

Group type: EXPERIMENTAL
Intervention: Acute moderate hypoxia (H)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxia (N)
Number of subjects: 8
Study: 10492489

Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention (education about cardiovascular risk factors, point-of-care cholesterol test, physician contact form)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care (brochure only, minimal follow-up)
Number of subjects: 1000
Study: 8621843

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 micrograms daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Loratadine 10 mg daily
Number of subjects: 240
Study: 2009156

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 6356688

Group type: EXPERIMENTAL
Intervention: Cefazolin plus metronidazole
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 59
Study: 30685106

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (n = 15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No psychotherapy (control group, n = 10)
Number of subjects: 25
Study: 27863126

Group type: EXPERIMENTAL
Intervention: Baseline weight
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Baseline perceived weight status
Number of subjects: 623
Study: 25953940

Group type: EXPERIMENTAL
Intervention: 3% saline compresses (Group A) 3 times weekly
Number of subjects: 78

Group type: COMPARATOR
Intervention: Mupirocine 2% ointment (Group B) 3 times weekly
Number of subjects: 78

Group type: COMPARATOR
Intervention: No aseptic agents (Group C)
Number of subjects: 78
Study: 23792806

Group type: EXPERIMENTAL
Intervention: Elicited pantomime
Number of subjects: 0
Study: 21352390

Group type: EXPERIMENTAL
Intervention: 12C (4 mm tip ablation catheter with 12 irrigation channels, 6 distal and 6 proximal)
Number of subjects: 95

Group type: COMPARATOR
Intervention: 6C (3.5 mm tip ablation catheter with 6 distal irrigation channels)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 12C
Number of subjects: 95

Group type: COMPARATOR
Intervention: 6C
Number of subjects: 95
Study: 19962601

Group type: EXPERIMENTAL
Intervention: Facial sensory-retraining exercises with standard opening exercises
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard opening exercises only
Number of subjects: 186
Study: 17178976

Group type: EXPERIMENTAL
Intervention: Low-dose quadruple antihypertensive combination (4 agents at one-quarter dosage; n=22)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Amlodipine (5 mg; n=22)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Atenolol (50 mg; n=20)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Bendroflumethiazide (2.5 mg; n=22)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Captopril (50 mg twice daily; n=22)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Low-dose quadruple antihypertensive combination
Number of subjects: 108

Group type: COMPARATOR
Intervention: Individual drugs (Amlodipine, Atenolol, Bendroflumethiazide, Captopril)
Number of subjects: 108
Study: 15595229

Group type: EXPERIMENTAL
Intervention: Topical ketoprofen 20% in a poloxamer-lecithin organogel (PLO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral 50-mg ketoprofen capsule
Number of subjects: 8
Study: 10802278

Group type: EXPERIMENTAL
Intervention: Nestorone alone (50, 75, 100 µg daily over 6 months)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol: Nestorone (30:100 and 15:150 µg daily over 6 months)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: ethinylestradiol:norethindrone acetate (20:1000 and 15:1000 µg daily over 4 months)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol:norethindrone acetate (20:1000 µg daily over 12 months)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (sexually active women from earlier study)
Number of subjects: 169
Study: 8644693

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (3.3‐3.5 mumol as chromium chloride or chromium picolinate)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chromium chloride or placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 36
Study: 2062620

Group type: EXPERIMENTAL
Intervention: HbOC vaccine (3-dose regimen, first dose between 6 weeks and 6 months, minimum interval of 1 month between doses, third dose by 1 year of age)
Number of subjects: 61080

Group type: EXPERIMENTAL
Intervention: HbOC vaccine (3-dose regimen)
Number of subjects: 61080

Group type: EXPERIMENTAL
Intervention: HbOC vaccine (1 dose)
Number of subjects: 61080

Group type: EXPERIMENTAL
Intervention: HbOC vaccine
Number of subjects: 61080
Study: 6339154

Group type: EXPERIMENTAL
Intervention: Physical exercise (standardized exercise programme, 1 hour twice weekly for 8 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Physical exercise (standardized exercise programme)
Number of subjects: 31
Study: 31706382

Group type: EXPERIMENTAL
Intervention: Schizophrenia diagnosis
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Antisocial traits/behaviors
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: White juveniles with antisocial traits
Number of subjects: 252
Study: 29353508

Group type: EXPERIMENTAL
Intervention: Aided communication
Number of subjects: 152

Group type: COMPARATOR
Intervention: Natural speech (reference group)
Number of subjects: 152
Study: 26367270

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI) for eight weeks
Number of subjects: 144
Study: 22429361

Group type: EXPERIMENTAL
Intervention: NUTRIOSE® 10 g/day for 14 days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: NUTRIOSE® 15 g/day for 14 days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: NUTRIOSE® 20 g/day for 14 days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: NUTRIOSE® 8 g/day for 14 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 20463176

Group type: EXPERIMENTAL
Intervention: Lactate-guided therapy (treatment guided by lactate levels aiming to decrease lactate by 20% or more per 2 hours for the initial 8 hours)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (no knowledge of lactate levels during the initial treatment period)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Lactate-guided therapy
Number of subjects: 348
Study: 19301628

Group type: EXPERIMENTAL
Intervention: Hand acupuncture treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 16306031

Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release (ER), 1000 mg once daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Clarithromycin immediate-release (IR), 500 mg bid
Number of subjects: 14
Study: 12410855

Group type: EXPERIMENTAL
Intervention: Lisinopril (up to 40 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Candesartan (up to 32 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination therapy (lisinopril up to 20 mg/day plus candesartan up to 16 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combination therapy vs Candesartan alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combination therapy vs Lisinopril only
Number of subjects: 45
Study: 10561307

Group type: EXPERIMENTAL
Intervention: Eniluracil 10 mg/m(2) twice daily for 3 days before surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eniluracil treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control patients
Number of subjects: 20
Study: 8659579

Group type: EXPERIMENTAL
Intervention: Gram-positive bacteria isolated from patients with confirmed growth (274 patients, 94.2%)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: All gram-positive isolates tested
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Seventeen gram-negative isolates (89%)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Two gram-negative isolates (11%)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Anterior chamber or secondary IOL implantations
Number of subjects: 420

Group type: COMPARATOR
Intervention: Posterior chamber IOL implantations or primary cataract extractions
Number of subjects: 420
Study: 1810355

Group type: EXPERIMENTAL
Intervention: Ames Multistix 10 dipstick
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Ames Multistix 10 dipstick tests for nitrite and leucocyte esterase
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Reflectance meter with Ames Multistix 10
Number of subjects: 615

Group type: COMPARATOR
Intervention: Common urinary symptoms (including incontinence)
Number of subjects: 615
Study: 6382999

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3806
Study: 30395812

Group type: EXPERIMENTAL
Intervention: RPC4046 180 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: RPC4046 360 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 29569535

Group type: COMPARATOR
Intervention: Vegetarian diet without supplementation (Veg+Pla, n=15)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vegetarian diet combined with daily β-alanine (0.8-0.4 g/d) and creatine supplementation (1 g creatine monohydrate/d) (Veg+Suppl, n=15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continued omnivorous diet (control, n=10)
Number of subjects: 40
Study: 26078286

Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine-supplemented parenteral nutrition (Gln-PN)
Number of subjects: 0
Study: 24794283

Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide (TA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Balanced salt solution (Control)
Number of subjects: 77
Study: 22270500

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) 3350 for 3 days outpatient
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Milk and molasses enema in the ED
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (PEG 3350)
Number of subjects: 79
Study: 19417589

Group type: EXPERIMENTAL
Intervention: Gabadone (amino acid preparation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17630491

Group type: EXPERIMENTAL
Intervention: Subcutaneous suturing of the subcutaneous fat tissue
Number of subjects: 415

Group type: COMPARATOR
Intervention: No subcutaneous suturing of the subcutaneous fat tissue
Number of subjects: 415
Study: 18162241

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (types 6, 11, 16, 18)
Number of subjects: 0
Study: 14999536

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (50 mg kg(‐1) intravenously for 3 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 10660922

Group type: EXPERIMENTAL
Intervention: Usual care plus acupressure training and treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 17
Study: 9120912

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG) therapy with isoniazid (300 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravesical bacillus Calmette-Guerin (BCG) therapy without isoniazid
Number of subjects: 0
Study: 8251274

Group type: EXPERIMENTAL
Intervention: Bupivacaine 12.5 mg with adrenaline 25 micrograms and sufentanil 10 micrograms (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bupivacaine 12.5 mg with adrenaline 25 micrograms and clonidine 30 micrograms (Group B)
Number of subjects: 50
Study: 2418328

Group type: EXPERIMENTAL
Intervention: Doxorubicin chemotherapy (60 mg/m2, i.v., given every 3 weeks, up to a maximum dose of 550 mg/m2)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: Surgically treated patients
Number of subjects: 66
Study: 11413601

Group type: EXPERIMENTAL
Intervention: 200 mg intravenous erythromycin
Number of subjects: 15
Study: 31921879

Group type: EXPERIMENTAL
Intervention: 42 g pistachios
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 g whole-wheat bread (WWB)
Number of subjects: 0
Study: 29232645

Group type: EXPERIMENTAL
Intervention: ERAS protocol (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital standard (control group)
Number of subjects: 0
Study: 26474232

Group type: EXPERIMENTAL
Intervention: Pilates + physical therapy (PPT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Physical therapy (PT) only
Number of subjects: 101
Study: 24913169

Group type: EXPERIMENTAL
Intervention: Single-dose primaquine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22367193

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 20163882

Group type: EXPERIMENTAL
Intervention: Endoscopic examination after adenoidectomy
Number of subjects: 312

Group type: COMPARATOR
Intervention: No endoscopic examination after adenoidectomy
Number of subjects: 312
Study: 18441625

Group type: EXPERIMENTAL
Intervention: Multi sensory behavior therapy (MSBT) with standard psychiatric inpatient care
Number of subjects: 24
Study: 16055834

Group type: EXPERIMENTAL
Intervention: Crisis card offering 24-h crisis telephone consultation
Number of subjects: 0
Study: 12168731

Group type: EXPERIMENTAL
Intervention: Depot goserelin (Group 1)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Daily leuprolide acetate (Group 2)
Number of subjects: 459
Study: 10442493

Group type: EXPERIMENTAL
Intervention: Tomato juice
Number of subjects: 15

Group type: COMPARATOR
Intervention: Synthetic orange drink
Number of subjects: 15
Study: 7874586

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 142
Study: 2230623

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) - single oral dose of 1, 2, 3, and 6 g
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) - daily doses of 0.12-24 g per kg body weight for six months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) - direct assay of anti-bacterial activity in water solution (25,000 mg per litre)
Number of subjects: 106
Study: 323811

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TM-SM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 20
Study: 31662863

Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) 90 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30053840

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 555

Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 555
Study: 27191767

Group type: EXPERIMENTAL
Intervention: Advanced formulation of megestrol acetate containing nanocrystals (test formulation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional formulation of megestrol acetate (reference formulation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 80
Study: 24877242

Group type: EXPERIMENTAL
Intervention: 22-G SF-EUS-FNA
Number of subjects: 120

Group type: COMPARATOR
Intervention: 25-G SF-EUS-FNA
Number of subjects: 120
Study: 23290218

Group type: EXPERIMENTAL
Intervention: Minimally invasive aortic valve replacement
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional aortic valve replacement
Number of subjects: 39
Study: 20563593

Group type: EXPERIMENTAL
Intervention: Intraoperative staining with methylene blue (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No intraoperative staining (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (experienced surgeons)
Number of subjects: 30
Study: 17386196

Group type: EXPERIMENTAL
Intervention: Portable NIOX MINO monitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: N‐6008 chemiluminescence analyzer
Number of subjects: 0
Study: 16779075

Group type: EXPERIMENTAL
Intervention: Electronic templates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dictation services
Number of subjects: 0
Study: 12559802

Group type: EXPERIMENTAL
Intervention: CAIV-T blended and filled at Medeva
Number of subjects: 225

Group type: COMPARATOR
Intervention: CAIV-T blended and filled at Aviron-PA
Number of subjects: 225
Study: 10802000

Group type: EXPERIMENTAL
Intervention: sublingual nitroglycerin (300 microg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: low-dose intravenous isoproterenol (mean infusion rate 1.3 +/- 0.5 microg/min)
Number of subjects: 71

Group type: COMPARATOR
Intervention: sublingual nitroglycerin test
Number of subjects: 71

Group type: COMPARATOR
Intervention: low-dose isoproterenol test
Number of subjects: 71
Study: 8895233

Group type: EXPERIMENTAL
Intervention: Ketamine (bolus at 0.1 mg/kg/5 min followed by an infusion of 7 micrograms/kg/min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 11
Study: 2072513

Group type: EXPERIMENTAL
Intervention: Lidocaine with 1:100,000 clonidine (n = 7)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Plain lidocaine (n = 8)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lidocaine with 1:200,000 clonidine (n = 6)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lidocaine with 1:200,000 epinephrine (n = 13)
Number of subjects: 34
Study: 6309710

Group type: EXPERIMENTAL
Intervention: Neutron irradiation twice weekly
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Neutron irradiation four times per week
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mixed-schedule irradiation (two neutron and three photon fractions per week)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional treatment (surgery, photon irradiation, or combined surgery and photon irradiation)
Number of subjects: 142
Study: 30754039

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Weight Stability (WS)
Number of subjects: 96
Study: 29431546

Group type: EXPERIMENTAL
Intervention: 5-week training protocol with traditional multijoint power resistance exercises, Olympic-style lifts, plyometric drills, and speed work (4 times per week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cessation of training (control group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5-week training protocol (experimental group)
Number of subjects: 22
Study: 26792218

Group type: EXPERIMENTAL
Intervention: Concurrent twice‐daily RT (45 Gy in 30 twice‐daily fractions over 3 weeks)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Concurrent once‐daily RT (66 Gy in 33 once‐daily fractions over 6.5 weeks)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 447
Study: 24918371

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CPAP plus weight-loss intervention
Number of subjects: 181

Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: All three groups (CPAP, weight loss, CPAP plus weight loss)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combined interventions (CPAP plus weight loss)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 181
Study: 21820142

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Non-CPAP group
Number of subjects: 215
Study: 19892345

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 100
Study: 18173141

Group type: EXPERIMENTAL
Intervention: Xiaokang Zhongzi Recipe (XZR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 110
Study: 16250037

Group type: EXPERIMENTAL
Intervention: Lamivudine plus rhIL-12 (500 ng/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lamivudine plus rhIL-12 (200 ng/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 15